MedPath

Obsidian Solutions Group Awarded AFWERX Contract for Virtual Emergency Response Training

• Obsidian Solutions Group received a $791,000 Direct-to-Phase II contract from AFWERX to develop virtual emergency response training. • The training program aims to enhance tactical team capabilities through advanced live, virtual, and constructive (LVC) exercises. • Obsidian's technology prototyping and demonstration were recognized as a viable solution for strengthening national defense. • The initiative supports the Department of the Air Force's efforts to streamline innovation and accelerate technology transition.

Obsidian Solutions Group has been awarded a Direct-to-Phase II contract by AFWERX, the innovation arm of the Department of the Air Force (DAF), to develop a Virtual Emergency Response training program. The contract, valued at $791,000, will focus on creating advanced Live, Virtual, and Constructive (LVC) training for tactical teams, addressing critical challenges within the DAF.
The Air Force Research Laboratory and AFWERX have partnered to expedite the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process. This collaboration aims to accelerate the experience of small businesses by providing faster proposal-to-award timelines, expanding opportunities, and reducing bureaucratic overhead through continuous process improvements in contract execution. Obsidian Solutions Group officially commenced its work on September 26, 2024.

Executive Commentary

Tyrone Logan, CEO of Obsidian Solutions Group, stated, “Obsidian’s selection to Phase 2 of the USAF SBIR for advanced technology prototyping and demonstration is one milestone in our pathway to growth in the RDT&E space. We are pleased our customer sees our advanced technology application as a potential, viable solution in support of the warfighter.”

About Obsidian Solutions Group

Obsidian Solutions Group is a provider of advanced technology solutions for defense and security applications, delivering training and operational support to military and government partners.

About AFRL

The Air Force Research Laboratory (AFRL) serves as the primary scientific research and development center for the Department of the Air Force. With over 12,500 personnel across nine technology areas and 40 operations globally, AFRL manages a diverse portfolio of science and technology.

About AFWERX

As the innovation arm of the DAF, AFWERX aims to integrate cutting-edge American ingenuity from small businesses and start-ups to address the DAF's most pressing challenges. Since 2019, AFWERX has executed over 6,200 new contracts worth more than $4.7 billion.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

AusperBio Secures $73 Million to Advance Chronic Hepatitis B Therapy

AusperBio has successfully completed a $73 million Series B financing round to advance its lead therapy, AHB-137, for a functional cure for chronic hepatitis B.
The funding will support Phase 2 clinical trials of AHB-137 in China and globally, along with the development of commercial-scale manufacturing processes.

Onward Medical's ARC-EX System Receives FDA Approval for Spinal Cord Injury Treatment

The FDA has granted de novo classification to Onward Medical's ARC-EX system, the first non-invasive spinal cord stimulator approved for SCI patients.
Clinical trials demonstrated that 90% of participants experienced improved strength or function, with 87% reporting a better quality of life.

SimX Awarded $1.25M AFWERX Grant to Enhance VR Medical Training for Expeditionary Support

SimX received a $1.25 million Phase II STTR grant from AFWERX to advance its Virtual Reality Medical Simulation System (VRMSS) for expeditionary medical support training.
The VR training aims to address critical challenges faced by the Department of the Air Force, focusing on perioperative surgical team preparedness in remote and challenging environments.

FDA Approves Medtronic's Affera System for Atrial Fibrillation Ablation

The FDA has approved Medtronic's Affera system, an all-in-one mapping and ablation solution, for treating atrial fibrillation (AFib).
The approval was based on the SPHERE PER-AF trial, which demonstrated the Affera system's non-inferiority to standard care in persistent AFib patients.

Oragenics' ONP-002 Shows Promise for Concussion Treatment, Prepares for Phase II Trials

Oragenics' ONP-002, a neurosteroid delivered intranasally, is advancing to Phase II clinical trials for treating moderate to severe concussions.
Pre-clinical studies demonstrated ONP-002's cardiac safety and non-genotoxicity, alongside successful completion of an FDA-recognized intranasal casting study.

Oshkosh Defense Submits Proposal for Robotic Combat Vehicle (RCV) Phase II

Oshkosh Defense has submitted its proposal for the U.S. Army's Robotic Combat Vehicle (RCV) Phase II program, aiming to provide innovative technologies for enhanced soldier performance.
The Oshkosh RCV is designed to be modular and payload agnostic, allowing for rapid integration of future technologies and adaptability in multi-domain operations.

Matregenix Secures $4.2M in Contracts to Advance Nanofiber Soft Tissue Repair

Matregenix has been awarded three Phase II Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) contracts from the Department of the Air Force (DAF).
The contracts, totaling over $4.2 million, will support the development of nanofiber technologies for soft tissue repair applications within the DAF.

Orphagen Pharmaceuticals Receives $2 Million NCI Grant for Novel ACC Therapy

Orphagen Pharmaceuticals secured a $2 million SBIR Phase II grant from the National Cancer Institute to advance OR-449, a first-in-class drug for adrenocortical carcinoma (ACC).
OR-449 is a selective inhibitor of steroidogenic factor-1 (SF-1), a key transcription factor crucial for adrenal gland development and implicated in ACC pathogenesis.

Reference News

[1]
Obsidian Solutions Group Secures Direct-to-Phase II Award from AFWERX to Enhance ...
morningstar.com · Oct 16, 2024

Obsidian Solutions Group secures $791,000 Direct-to-Phase II AFWERX contract for advanced LVC training to enhance emerge...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy